Format

Send to

Choose Destination
See comment in PubMed Commons below
AIDS. 2007 Jun 19;21(10):1229-31.

The obligation to provide antiretroviral treatment in HIV prevention trials.

Author information

1
Program in Medical Ethics, Center for AIDS Prevention Studies and Division of General Internal Medicine, University of California San Francisco, San Francisco, CA, USA.

Abstract

Providing antiretroviral therapy (ART) to participants who seroconvert during HIV prevention trials in developing countries is an ethical expectation. Promising treatment to the few seroconverters widens disparities within a resource-poor country and would be unjust. Such an assurance should be done in a way that also improves access to ART for others in the country. US funds for ART in poor countries from the PEPFAR should be available to all countries that host HIV prevention and clinical trials.

PMID:
17545698
DOI:
10.1097/QAD.0b013e3281338371
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center